Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: A systematic review and cost-effectiveness analysis

Health Technology Assessment

Volumn 18, Issue 18, 2014, Pages 1-106

  Whiting, Penny ^a   Al Maiwenn, ^b   Burgers, Laura ^b   Westwood, Marie ^a   Ryder, Steve ^a   Hoogendoorn, Martine ^b   Armstrong, Nigel ^a   Allen, Alex ^a   Severens, Hans ^b   Kleijnen, Jos ^a  

^a KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CHLORIDE; GLYCINE; IVACAFTOR; PLACEBO; AMINOPHENOL DERIVATIVE; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; AGE; AMINO ACID SUBSTITUTION; ARTICLE; BODY WEIGHT; CHILD HEALTH CARE; CHLORIDE SWEAT LEVEL; COST EFFECTIVENESS ANALYSIS; COUGHING; CRACKLE; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEVER; FORCED EXPIRATORY VOLUME; G551D GENE; GENE; GENE MUTATION; HEADACHE; HEMOPTYSIS; HUMAN; LUNG DISEASE; LUNG FUNCTION; LUNG INJURY; LUNG TRANSPLANTATION; NAUSEA; NOSE OBSTRUCTION; OPEN STUDY; OROPHARYNX PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINOPHARYNGITIS; SIMULATION; SWEAT; SYSTEMATIC REVIEW; TREATMENT INDICATION; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADOLESCENT; ADULT; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENETICS; LUNG FUNCTION TEST; MALE; MUTATION; NATIONAL HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SEX DIFFERENCE; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE FACTORS; AMINOPHENOLS; CHILD; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; ENGLAND; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MODELS, ECONOMIC; MUTATION; QUALITY-ADJUSTED LIFE YEARS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; SEX FACTORS; STATE MEDICINE;

EID: 84897399962     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18180     Document Type: Article

References (109)

1. Cystic Fibrosis Trust. Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK. 2nd ed. London: Cystic Fibrosis Trust; December 2011. URL: www.cysticfibrosis.org.uk/media/82070/CD_Standards_of_Care_Dec_11.pdf (accessed 7 May 2012).
2. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-6. http://dx.doi.org/10.1183/09031936.00099506
3. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938;56:344-99. http://dx.doi.org/10.1001/archpedi.1938.01980140114013
4. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med 2006;173:475-82. http://dx.doi.org/10.1164/rccm.200505-840OE
5. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-80. http://dx.doi.org/10.1126/science.2570460
6. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-14. http://dx.doi.org/10.1016/j.jpeds.2008.05.005
7. The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993;329:1308-13.
8. UK CF Registry. Annual Data Report 2010. Bromley, Kent: Cystic Fibrosis Trust; 2011. URL: www.cysticfibrosis.org.uk/about-cf/publications/cf-registry-reports.aspx (accessed 12 June 2012).
9. Public Health England. The UK NSC Policy on Cystic Fibrosis Screening in Newborns. London: UK Screening Portal; 2012. URL: www.screening.nhs.uk/cysticfibrosis-newborn (accessed 8 May 2012).
10. UK Newborn Screening Programme Centre. Figure 1. CF screening flow chart. In A Laboratory Guide to Newborn Screening in the UK for Cystic Fibrosis. 3rd edn. London: UK Newborn Screening Programme Centre; 2009. URL: http://newbornbloodspot.screening.nhs.uk/getdata.php?id=10967 (accessed 8 May 2012).
11. Serra-Prat M. Neonatal Screening for Cystic Fibrosis. BR01/2000. Barcelona: Catalan Agency for Health Technology Assessment (CAHTA); 2000. URL: www.gencat.cat/salut/depsan/units/aatrm/pdf/br0001en.pdf (accessed 8 May 2012).
12. Davis PB, Yasothan U, Kirkpatrick P. Ivacaftor. Nat Rev Drug Discov 2012;11:349-50. http://dx.doi.org/10.1038/nrd3723
13. European Medicines Agency. Orphan Designation. London: European Medicines Agency; 2012. URL: www.emea.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&mid=WC0b01ac05800240ce (accessed 8 May 2012).
14. U.S. Food and Drug Administration (FDA). FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis. FDA news release. Silver Spring, MD: FDA; 2012. URL: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=Kalydeco&utm_content=1 (accessed 8 May 2012).
15. Vertex Pharmaceuticals Inc. Vertex Receives European Approval for Kalydeco™ (Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People withaSpecific Genetic Mutation (G551D). Press release, 27 July 2012. URL: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=696069 (accessed 15 August 2012).
16. Vertex Pharmaceuticals Inc. Ivacaftor for the Management of Cystic Fibrosis. Formulary Submission Dossier. Cambridge, MA: Vertex Pharmaceuticals Inc.; 2012.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9. http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00135
18. Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: University of York; 2009. URL: www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.htm (accessed 9 July 2012).
19. McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evidence Based Libr Inform Prac 2010;5:1-6.
20. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. http://dx.doi.org/10.1136/bmj.d5928
21. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72.
22. Ramsey B, Dong Q, Yen K, Elborn J. Efficacy and safety of VX-770 in subjects with cystic fibrosis and the G551DCFTR mutation. Paper presented at the 25th North American Cystic Fibrosis Conference, Anaheim, CA, 2-5 November 2011. Pediatr Pulmonol 2011;46:286-7.
23. Borowitz D, Ramsey B, Dong Q, Yen K, Elborn JS. Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation [WS6.3]. Paper presented at 35th European Cystic Fibrosis Conference, Dublin, Ireland, 6-9 June 2012. J Cyst Fibros 2012;11(Suppl. 1):13.
24. Quittner AL, Ramsey B, Dong Q, Yen K, Elborn JS. Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation. Paper presented at 35th European Cystic Fibrosis Conference, Dublin, Ireland, 6-9 June 2012. J Cyst Fibros 2012;11(Suppl. 1):67.
25. Griese M, Ramsey B, Rodriguez S, Yen K, Elborn JS. Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation. Paper presented at 35th European Cystic Fibrosis Conference, Dublin, Ireland, 6-9 June 2012. J Cyst Fibros 2012;11(Suppl. 1):67.
26. Vertex Pharmaceuticals Inc., Cystic Fibrosis Foundation. Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older with the G551D Mutation. Bethesda, MD: National Library of Medicine (US); 2011. URL: http://ClinicalTrials.gov/show/NCT00909532 (accessed 29 June 2012).
27. Aherns R, Rodriguez S, Yen K, Davies JC. VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551D-CFTR mutation. Paper presented at the 25th North American Cystic Fibrosis Conference, Anaheim, CA, 3-5 November 2011. Pediatr Pulmonol 2011;46:283.
28. Davies JC, Li H, Yen K, Ahrens R. Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation [WS6.5]. Paper presented at 35th European Cystic Fibrosis Conference, Dublin, Ireland, 6-9 June 2012. J Cyst Fibros 2012;11(Suppl. 1):13.
29. Vertex Pharmaceuticals Inc. Phase 3 Study of KALYDECO (Ivacaftor) in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks. Press release, 3 November 2011.
30. Vertex Pharmaceuticals Inc. Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years with the G551D Mutation (ENVISION). Bethesda, MD: National Library of Medicine (US); 2012. URL: http://clinicaltrials.gov/ct2/show/NCT00909727 (accessed 28 June 2012).
31. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright CE, et al. Long-term safety and efficacy of investigational CFTR potentiator, VX-770, in subjects with CF [abstract 204]. Paper presented at the 25th North American Cystic Fibrosis Conference, 2-5 November 2011, Anaheim, CA. Pediatr Pulmonol 2011;46:284.
32. McKone E, Li H, Yen K, Davies JC. Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation [WS6.4]. Paper presented at 35th European Cystic Fibrosis Conference, Dublin, Ireland, 6-9 June 2012. J Cyst Fibros 2012;11(Suppl. 1):13.
33. Vertex Pharmaceuticals Inc., Cystic Fibrosis Foundation. Study of VX-770 in Cystic Fibrosis Subjects. Bethesda, MD: National Library of Medicine (US); 2012. URL: http://ClinicalTrials.gov/show/NCT01117012 (accessed 29 June 2012).
34. Center for Drug Evaluation and Research. Summary Review of Regulatory Action: Ivacaftor [Application number: 203188Orig1s000]. Silver Spring, MD: FDA; 2011.
35. Center for Drug Evaluation and Research. Medical Review: Ivacaftor [Application number: 203188Orig1s000]. Silver Spring, MD: FDA; 2011.
36. Center for Drug Evaluation and Research. Statistical Review and Evaluation: Ivacaftor [Application number: 203188Orig1s000]. Silver Spring, MD: FDA; 2011.
37. Royal Brompton & Harefield NHS Foundation Trust. Clinical guideline 9: transplant assessment. In Balfour-Lynn I, editor. Clinical Guidelines: Care of Children with Cystic Fibrosis 2011. London: Royal Brompton & Harefield NHS Foundation Trust; 2011. URL: www.rbht.nhs.uk/healthprofessionals/clinical-departments/paediatrics/childrencf/transplant-assessment/ (accessed 6 July 2012).
38. Simpson N, Anderson R, Sassi F, Pitman A, Lewis P, Tu K, et al. The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model. Cost Eff Resour Alloc 2005;3:1-11.
39. Thornton J, Elliott RA, Tully MP, Dodd M, Webb AK. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros 2005;4:239-47. http://dx.doi.org/10.1016/j.jcf.2005.08.003
40. Baumann U, Stocklossa C, Greiner W, von der Schulenburg J-MG, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003;2:84-90. http://dx.doi.org/10.1016/S1569-1993(03)00024-9
41. National Institute for Health and Care Excellence. Colistimethate Sodium and Tobramycin Dry Powders for Inhalation for Treating Pseudomonas Lung Infection in Cystic Fibrosis. NICE technology appraisal guidance TA276. London: NICE; 2013. URL: http://guidance.nice.org.uk/TA276/Guidance/pdf/English (accessed 13 September 2013).
42. Riemsma R, Al MJ, Armstrong N, Misso K, Allen A, Manning N, et al. Mannitol Dry Powder for Inhalation for the Treatment of Cystic Fibrosis: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd; 2011.
43. Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Validation of the SF-36 for the assessment of quality of life in adolescents and adults with cystic fibrosis. J Cyst Fibros 2002;1:137-45. http://dx.doi.org/10.1016/S1569-1993(02)00079-6
44. UK Cystic Fibrosis Registry. The UK CF Registry homepage. URL: www.cysticfibrosis.org.uk/who-we-are/driving-up-standards/uk-cf-registry.aspx (accessed 12 September 2013).
45. Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55:946-54. http://dx.doi.org/10.1136/thorax.55.11.946
46. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. London: NICE; 2008.
47. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52. http://dx.doi.org/10.1093/aje/153.4.345
48. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62:360-7. http://dx.doi.org/10.1136/thx.2006.060889
49. NHS Blood and Transplant. Transplant Activity in the UK 2009/10. London: NHS Blood and Transplant; 2010. URL: www.nhsbt.nhs.uk/downloads/pdfs/temp/report.pdf (accessed 6 July 2012).
50. Office for National Statistics. England and Wales Interim Life Tables. London: Office for National Statistics; 2011. URL: www.gad.gov.uk/Demography%20Data/Life%20Tables/Interim_life_tables.html (accessed 15 August 2013).
51. Konstan MW, Accurso FJ, Boyle MP, Clancy JP, Ordonez CL, Zha J, et al. Relationship between pulmonary outcomes, biomarkers of CF disease, and serum drug levels in subjects with the G551D-CFTR mutation treated with VX-770, an investigational oral potentiator of CFTR. Paper presented at American Thoracic Society International Conference, New Orleans, LA, 14-19 May 2010. Am J Respir Crit Care Med 2010;181:A2336.
52. Konstan MW, Wagener JS, Vandevanter DR, Pasta DJ, Yegin A, Rasouliyan L, et al. Risk factors for rate of decline in FEV(1) in adults with cystic fibrosis. J Cyst Fibros 2012;11:405-11.
53. Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012;11:78-83. http://dx.doi.org/10.1016/j.jcf.2011.10.003
54. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. CHE Discussion Paper 172. York: Centre for Health Economics, University of York; 1999. URL: www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf (accessed 9 July 2012).
55. Rutten-van Molken MPMH, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does uality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006;130:1117-28. http://dx.doi.org/10.1378/chest.130.4.1117
56. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax 2001;56:218-22. http://dx.doi.org/10.1136/thorax.56.3.218
57. Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800. http://dx.doi.org/10.1177/0272989X11401031
58. Vertex Pharmaceuticals Inc. Examination of Costs and Utilization Associated with Progression of Cystic Fibrosis. Final Report; 2010.
59. Cystic Fibrosis Trust. Antibiotic Treatment for Cystic Fibrosis. 2nd edn. London: Cystic Fibrosis Trust; 2009.
60. Corey M. Power considerations for studies of lung function in cystic fibrosis. Proc Am Thorac Soc 2007;4:334-7. http://dx.doi.org/10.1513/pats.200611-176HT
61. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72. http://dx.doi.org/10.1542/peds.103.6.e72
62. Department of Health. Cystic Fibrosis Guidance. Leeds: Department of Health; 2012. URL: www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_132357 (accessed 28 June 2012).
63. UK CF Registry. Apply for Data from the CF Registry. Bromley: Cystic Fibrosis Trust; 2012. URL: www.cysticfibrosis.org.uk/our-research/apply-for-data-from-the-cf-registry.aspx (accessed 12 June 2012).
64. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 63, March 2012. London: BMA and RPS; 2012. URL: www.bnf.org (accessed 9 July 2012).
65. Department of Health. NHS Reference Costs 2010-11. London: Department of Health; 2012. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131140 (accessed 6 July 2012).
66. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. An economic evaluation of lung transplantation. J Thorac Cardiovasc Surg 2002;123:411-18; discussion 418-20. http://dx.doi.org/10.1067/mtc.2002.120342
67. Curtis L. Unit Costs of Health and Social Care 2009. Canterbury: PSSRU, University of Kent; 2009. URL: www.pssru.ac.uk/archive/pdf/uc/uc2009/uc2009.pdf (accessed 9 July 2012).
68. Curtis L. Unit Costs of Health and Social Care 2011. Canterbury: PSSRU, University of Kent; 2011. URL: www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf (accessed 9 July 2012).
69. National Institute for Health and Care Excellence. Appraising Orphan Drugs [draft v3]. London: NICE; 2006. URL: www.nice.org.uk/aboutnice/whoweare/seniormanagementteam/seniormanagementteammeetings/2005/12july2005/appraising_orphan_drugs.jsp (accessed 10 July 2012).
70. This is my: limited. Genetic: Cystic Fibrosis Genetic Screening [Cost per Test]. Leeds: Thisismy: Health Screening & Ultrasound Centre. URL: www.thisismy.co.uk/genetic-screening-dna-testing-pricelist/ (accessed 9 July 2012).
71. George PM, Banya W, Pareek N, Bilton D, Cullinan P, Hodson ME, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011;342:d1008. http://dx.doi.org/10.1136/bmj.d1008
72. Sanders DB, Bittner RCL, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32. http://dx.doi.org/10.1164/rccm.200909-1421OC
73. Sanders DB, Bittner RCL, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400. http://dx.doi.org/10.1002/ppul.21374
74. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72. http://dx.doi.org/10.1378/chest.121.1.64
75. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. prevention. Thorax 2007;62:723-32. http://dx.doi.org/10.1136/thx.2006.060897
76. Gee L, Abbott J, Hart A, Conway SP, Etherington C, Webb AK. Associations between clinical variables and quality of life in adults with cystic fibrosis. J Cyst Fibros 2005;4:59-66. http://dx.doi.org/10.1016/j.jcf.2004.12.005
77. Flume PA, Borowitz DS, Liou TG, Li H, Yen K, Ordonez CL, et al. VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Paper presented at 34th European Cystic Fibrosis Conference, Hamburg, Germany, 8-11 June 2011. J Cyst Fibros 2011;10:S16.
78. Flume PA, Borowitz D, Liou T, Li H, Yen K, Ordonez C, et al. VX-770 in subjects with CF and homozygous for the F508del-CFTR mutation. Paper presented at 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, 3-5 November 2011. Pediatr Pulmonol 2011;46:284-5.
79. Boyle MP, Bell S, Konstan MW, McColley SA, Wisseh S, Spencer-Green G. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508del-CFTR mutation. Paper presented at 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, 3-4 November 2011. Pediatr Pulmonol 2011;46:287.
80. North of England Specialised Commissioning Group. Statement from North of England SCG on Behalf of the Four Specialised Commissioning Groups in England: Ivacaftor (Brand Name Kalydeco) for Cystic Fibrosis. Barnsley: NHS Barnsley; 2012. URL: www.yhscg.nhs.uk/Downloads/Ivacaftor/IVACAFTOR_19%2012%202012%20ne_FINAL%20DECISION.pdf (accessed 6 February 2013).
81. Wertz DA, Chang C-L, Stephenson JJ, Zhang J, Kuhn RJ. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. J Med Econ 2011;14:759-68. http://dx.doi.org/10.3111/13696998.2011.621004
82. Briesacher BA, Quittner AL, Fouayzi H, Zhang J, Swensen A. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. Pediatr Pulmonol 2011;46:770-6. http://dx.doi.org/10.1002/ppul.21441
83. O'Sullivan AK, Sullivan J, Higuchi K, Montgomery AB. Health care utilization & costs for cystic fibrosis patients with pulmonary infections. Manag Care 2011;20:37-44.
84. Woodward TC, Brown R, Sacco P, Zhang J. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. J Med Econ 2010;13:492-9.
85. Braccini G, Festini F, Boni V, Neri AS, Galici V, Campana S, et al. The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Chemother 2009;21:188-92.
86. Schreyogg J, Hollmeyer H, Bluemel M, Staab D, Busse R. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006;24:999-1009.
87. van den Akker, van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006;118:896-905. http://dx.doi.org/10.1542/peds.2005-2782
88. Iles R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J Cyst Fibros 2003;2:120-8. http://dx.doi.org/10.1016/S1569-1993(03)00064-X
89. Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ 2012;15:219-24.
90. Dewitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, et al. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health 2012;15:277-83. http://dx.doi.org/10.1016/j.jval.2011.11.027
91. Abbott J, Hart A, Morton AM, Dey P, Conway SP, Webb AK. Can health-related quality of life predict survival in adults with cystic fibrosis? Am J Respir Crit Care Med 2009;179:54-8. http://dx.doi.org/10.1164/rccm.200802-220OC
92. Becker CC, Vieira MC, Harrow B, Liou TG, Jansen JP. Disease progression in cystic fibrosis-synthesis of survival evidence. Paper presented at 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, MD, 21-25 May 2011. Value Health 2011;14:A138.
93. Loadman M, Holman J, Jackson K, Weinkauf J, Roland N, Kapasi A, et al. Trends in the functional outcomes and quality of life of cystic fibrosis patients following lung transplant. Paper presented at 30th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, Chicago, IL, 21-24 April 2010. J Heart Lung Transplant 2010;29(Suppl. 2):125-6.
94. Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatr 2009;9:55. http://dx.doi.org/10.1186/1471-2431-9-55
95. Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2009;1:CD003884. DOI: 10.1002/14651858.CD003884.pub3.
96. Weiner JR, Toy EL, Sacco P, Duh MS. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother 2008;9:751-66. http://dx.doi.org/10.1517/14656566.9.5.751
97. Guerriere DN, Tranmer JE, Ungar WJ, Manoharan V, Coyte PC. Valuing care recipient and family caregiver time: a comparison of methods. Int J Technol Assess Health Care 2008;24:52-9. http://dx.doi.org/10.1017/S0266462307080075
98. Radhakrishnan M, van Gool K, Hall J, Delatycki M, Massie J. Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 2008;85:133-47. http://dx.doi.org/10.1016/j.healthpol.2007.07.007
99. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005;2:CD002007. DOI: 10.1002/14651858.CD002007.pub2.
100. Yi MS, Tsevat J, Wilmott RW, Kotagal UR, Britto MT. The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference? J Pediatr 2004;144:711-18. http://dx.doi.org/10.1016/j.jpeds.2004.02.032
101. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009;2:CD001506. DOI: 10.1002/14651858.CD001506.pub3.
102. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-7. http://dx.doi.org/10.1513/pats.200703-040BR
103. Ashish A, Nazareth D, Tsoulkani A, Priona G, Harris M, Ledson M, et al. Social deprivation and clinical outcomes in adult CF patients. Paper presented at British Thoracic Society Winter Meeting, London, UK, 1-3 December 2010. Thorax 2010;65:A120.
104. Smalarz A, Harrow B, Pashos CL, Schoeman O. Cost of pseudomonas aeruginosa in cystic fibrosis patients in the United Kingdom. Paper presented at ISPOR 14th Annual International Meeting, Orlando, FL, 16-20 May 2009. Value Health 2009;12:A192.
105. Abbott J, Hart A, Havermans T, Matossian A, Goldbeck L, Barreto C, et al. Measuring health-related quality of life in clinical trials in cystic fibrosis. J Cyst Fibros 2011;10(Suppl. 2):82-5. http://dx.doi.org/10.1016/S1569-1993(11)60013-1
106. Elborn JS. Key advances along the CF pipeline. Paper presented at 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, 3-5 November 2011. Pediatr Pulmonol 2011;46:179-80.
107. Hofer M, Fiechter Lienert B, Kurowski T, Boehler A. Correlation of physical performance and quality of life in adult patients with cystic fibrosis. Paper presented at Joint Annual Meeting of the Swiss Respiratory Society, Swiss Society of Oto-Rhino-Laryngology, Head and Neck Surgery, Swiss Paediatric Respiratory Society, Swiss Society for Thoracic Surgery, Interlaken, Switzerland, 4-6 May 2011. Respiration 2011;81:94.
108. Bradley J, Blume S, Bal MM, Honeybourne D, Elborn JS. Health related quality of life (HRQoL) and health utility in patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa (PA) infection in the UK. Paper presented at 34th European Cystic Fibrosis Conference, Hamburg, Germany, 8-11 June 2011. J Cyst Fibros 2011;10:S88.
109. Ratjen F, Grasemann H. New therapies in cystic fibrosis. Curr Pharm Des 2012;18:614-27. http://dx.doi.org/10.2174/138161212799315984